Argos to present on HIV treatment at conference

Argos to present on HIV treatment, pathogenesis, and prevention at conference
Argos to present on HIV treatment, pathogenesis, and prevention at conference | Courtesy of
Argos Therapeutics Inc., a biopharmaceutical company, recently announced that company representatives will give a presentation at the eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

Argos is dedicated to developing and commercializing fully personalized immunotherapies for treating cancer and infectious diseases. The company uses the Arcelis technology platform for these developments.

The representative will be Irina Tcherepanova, the director of molecular biology at Argos. The event will be hosted by the Vancouver Convention Centre in Vancouver, British Columbia, Sunday through Wednesday.

Tcherepanova is scheduled to participate in the conference’s roundtable discussion about combination therapy trials. The discussion will take place as part of the event’s symposium, “Towards an HIV Cure,” Saturday. Her post presentation is titled “Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA-pulsed DC therapy,” which is Tuesday.

The IAS Conference will feature the most recent advances in HIV science, which includes the clinical, basic and prevention research of the industry. This event unites a broad variety of HIV professionals who travel from locations around the world to attend the conference.

Organizations in this Story

Argos Therapeutics Inc

Want to get notified whenever we write about Argos Therapeutics Inc ?
Next time we write about Argos Therapeutics Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.